Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
CDNA vs NDRA: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
CDNA Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 8–2 Matrix Metrics)
CDNA Overall Winner
6-Pillar Tally: CDNA 6 – 0 NDRA
Matrix Metrics: CDNA 8 – 2 NDRA
As of Nov 16, 2026, CareDx, Inc. (CDNA) is the stronger overall head-to-head candidate over ENDRA Life Sciences Inc. (NDRA) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CDNA carries a Unified Composite Score of 24.5/100 (STRONG SELL) at $73.72 (47.1x Forward P/E, 1.6% operating margin), whereas NDRA carries 44.7/100 (HOLD) at $4.42 (N/M Forward P/E, 0.0% operating margin).
- Composite vs. Pillar Nuance: While NDRA currently prints a higher short-term Unified Composite Score (44.7/100 HOLD vs. CDNA 24.5/100 STRONG SELL), CDNA captures the overall institutional head-to-head verdict (8–2 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (1.6% vs. 0.0% operating margin) and revenue trajectory (+39.3% vs. +0.0% YoY).
- Technical & Structure Timing Caution: CDNA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 49.0); meanwhile NDRA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About CDNA vs NDRA
CDNA
Head-to-Head Winner
CareDx, Inc.
$73.72
-5.34% 1D
Market Cap
$4.1B
TTM Revenue
$497M
Forward P/E
47.1x
Beta / 30D Vol
1.21β · 98% Vol
Unified Composite Score
24.5
STRONG SELL
Tech 15.0
Fund 36.0
Flow 70.0
Mom 25.9
Weinstein Technical Phase
Neutral · Hold
NDRA
ENDRA Life Sciences Inc. Common Stock
$4.42
+0.23% 1D
Market Cap
$6.6M
TTM Revenue
N/A
Forward P/E
N/M
Beta / 30D Vol
0.71β · 48% Vol
Unified Composite Score
44.7
HOLD
Tech 35.0
Fund 46.0
Flow 50.0
Mom 60.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (CDNA 6 – 0 NDRA)
1. Valuation Multiples
CDNA
Forward P/E
47.1x
N/M
Trailing P/E
32.9x
N/M
PEG Ratio
N/M
N/M
EV / Revenue
7.8x
N/M
2. Growth & Scale
CDNA
Revenue Growth (YoY)
+39.3%
+0.0%
Earnings Growth (YoY)
N/A
+0.0%
TTM Revenue (USD)
$497M
N/A
Market Cap
$4.1B
$6.6M
3. Profitability & Quality
CDNA
Gross Margin
71.0%
N/A
Operating Margin
1.6%
0.0%
Net Profit Margin
25.9%
0.0%
Return on Equity (ROE)
33.0%
-152.0%
4. Balance Sheet & Cash Flow
CDNA
Cash Generation (TTM)
$60M
-$8.0M
Cash Flow Margin
12.0%
N/A
Net Cash / Leverage
$221M Net Cash
$104,744 Net Debt (0.26x D/E)
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
CDNA
Options Structure Phase
CONSOLIDATION
UNCLASSIFIED
Current IV / %ile
56.8% (18th %ile)
N/A (N/A)
Put/Call OI Skew
1.04x (Balanced)
N/A
OBV Trend / Tech Phase
NEUTRAL · Neutral
NEUTRAL · Markdown
6. R&D & Supply-Chain Moat
CDNA
OpEx & R&D Intensity
69.4% of Rev ($345M)
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Scale & Operating Efficiency Moat
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Diagnostics & Research Operator
Diagnostics & Research Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: CDNA (8) vs NDRA (2)| Institutional Metric | CDNA | NDRA | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $4.1B | $6.6M | CDNA | |
| Trailing P/E Ratio | 32.9x | N/M | CDNA | |
| Forward P/E Ratio | 47.1x | N/M | CDNA | |
| Revenue Growth (YoY) | +39.3% | +0.0% | CDNA | |
| Operating Margin (TTM) | 1.6% | 0.0% | CDNA | |
| Net Profit Margin | 25.9% | 0.0% | CDNA | |
| Return on Equity (ROE) | 33.0% | -152.0% | CDNA | |
| 52-Week Range Position | 77% ($15–$91) | 37% ($3–$7) | CDNA | |
| Beta / 30D Volatility | 1.21β · 98% Vol | 0.71β · 48% Vol | NDRA | |
| Unified Institutional Score | 24.5 / 100 (STRONG SELL) | 44.7 / 100 (HOLD) | NDRA | |
| Trailing 12M Revenue (USD) | $497M | N/A | Scale | |
| Gross Profit Margin (TTM) | 71.0% | N/A | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 7.8x EV/Rev | N/M PEG · N/M EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | $60M ($221M Net Cash) | -$8.0M ($104,744 Net Debt (0.26x D/E)) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
CDNA +21.94 pp
3M Horizon
CDNA +61.64 pp
6M Horizon
CDNA +276.34 pp
1Y Horizon
CDNA +397.24 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | CDNA Revenue | NDRA Revenue | CDNA Op. Margin | NDRA Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | $80M | $0M | -20.3% | -146080.5% | CDNA |
| FY2019 | $130M | N/A | -19.3% | N/A | CDNA |
| FY2020 | $190M | N/A | -11.7% | N/A | CDNA |
| FY2021 | $300M | N/A | -10.0% | N/A | CDNA |
| FY2022 | $320M | N/A | -24.0% | N/A | CDNA |
| FY2023 | $280M | N/A | -72.5% | N/A | CDNA |
| FY2024 | $330M | N/A | 12.2% | N/A | CDNA |
| FY2025 | $380M | N/A | -8.1% | N/A | CDNA |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
CDNA
CONSOLIDATION
Current IV
56.8%
IV Percentile
18th %ile
Put/Call OI Skew
1.04x (Balanced)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact CDNA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
NDRA
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact NDRA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
CDNA Moat Profile
Scale & Operating Efficiency Moat
Diagnostics & Research Operator
OpEx & R&D Reinvestment
69.4% of Rev ($345M)
90D Engineering Disclosures
0 Published
NDRA Moat Profile
Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ CDNA vs NDRA Key Questions & Quantitative Answers
As of Nov 16, 2026, CareDx, Inc. (CDNA) is the stronger overall head-to-head candidate over ENDRA Life Sciences Inc. (NDRA) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CDNA carries a Unified Composite Score of 24.5/100 (STRONG SELL) at $73.72 (47.1x Forward P/E, 1.6% operating margin), whereas NDRA carries 44.7/100 (HOLD) at $4.42 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While NDRA currently prints a higher short-term Unified Composite Score (44.7/100 HOLD vs. CDNA 24.5/100 STRONG SELL), CDNA captures the overall institutional head-to-head verdict (8–2 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (1.6% vs. 0.0% operating margin) and revenue trajectory (+39.3% vs. +0.0% YoY). Technical & Structure Timing Caution: CDNA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 49.0); meanwhile NDRA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
CDNA leads the Growth & Scale pillar: CDNA posts +39.3% YoY revenue growth and N/A YoY earnings growth on $497M TTM revenue (71.0% gross margin, 1.6% operating margin), compared with NDRA at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), CDNA cumulative revenue shifted +375.0% while NDRA shifted N/A. In operating R&D and SG&A reinvestment, CDNA deploys 69.4% of Rev ($345M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for NDRA.
CDNA screens cheaper on headline valuation multiples. CDNA trades at 47.1x Forward P/E, 32.9x Trailing P/E, N/M PEG, and 7.8x EV/Revenue (12.0% FCF margin), whereas NDRA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CDNA (33.0% ROE) versus NDRA (-152.0% ROE) capital efficiency.
In options market volatility and institutional positioning, CDNA carries 56.8% implied volatility (18th %ile, Compressed (<25th %ile)), a 1.04x (Balanced) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.21β · 98% Vol realized risk). By comparison, NDRA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.71β · 48% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
NDRA vs CDNA · Reverse Pair
CDNA vs TWST
· Sector Peer
CDNA vs PSNL
· Sector Peer
CDNA vs VCYT
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma
AVGO vs MRVL
· Custom ASIC & Networking